Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 May;50(2):255-267.
doi: 10.1016/j.rdc.2024.02.001.

Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica

David F L Liew  1 , Sarah L Mackie  2 , Alice Tison  3 , Sebastian E Sattui  4 , Max Yates  5 , Russell R C Buchanan  6 , Claire E Owen  6
Affiliations
Review

Immune Checkpoint Inhibitor-induced Polymyalgia Rheumatica

David F L Liew et al. Rheum Dis Clin North Am. 2024 May.

Abstract

Polymyalgia rheumatica (PMR) immune-related adverse events (ICI-PMRs) represent a novel, distinct entity, despite many clinical, laboratory, and imaging similarities to classical PMR. Important questions remain in differentiating ICI-PMR from classical PMR, as well as other immune-related adverse events and PMR mimics. Despite this, ICI-PMR currently takes treatment cues from classical PMR, albeit with considerations relevant to cancer immunotherapy. Comparisons between ICI-PMR and classical PMR may provide further bidirectional insights, especially given that important questions remain unanswered about both diseases. The cause of classical PMR remains poorly understood, and ICI-PMR may represent a model of induced PMR, with important therapeutic implications.

Keywords: Disease model; Immune-related adverse event; Mimics; PD-1 agonist; PD-1 inhibitor; Paraneoplastic; Peresolimab; Polymyalgia rheumatica.

PubMed Disclaimer

Conflict of interest statement

Disclosure No specific funding was received from any bodies in the public, commercial or not-for-profit sectors to carry out the study described in this article. D.F.L. Liew and R.R.C. Buchanan declare no relevant interests. C.E. Owen declares: consultancy and advisory board participation for Abbvie; speaking honoraria from Abbvie, Janssen, Novartis, and Roche. A. Tison declares consulting fees from Galapagos, speakers bureaus from Bristol-Myers Squibb, congress fees: Sanofi and Abbvie. S.L. Mackie reports: Consultancy on behalf of her institution for Roche/Chugai, Sanofi, AbbVie, AstraZeneca, and Pfizer; Investigator on clinical trials for Sanofi, GSK, and Sparrow; speaking/lecturing on behalf of her institution for Roche/Chugai, Vifor, Pfizer, UCB, Novartis, and AbbVie; chief investigator on STERLING-PMR trial, funded by the National Institute for Health and Care Research (NIHR); patron of the charity PMRGCAuk. No personal remuneration was received for any of the above activities. Support from Roche/Chugai to attend EULAR2019 in person and from Pfizer to attend ACR Convergence 2021 virtually. S.L. Mackie is supported in part by the NIHR Leeds Biomedical Research Center. The views expressed in this article are those of the authors and not necessarily those of the NIHR, the NIHR Leeds Biomedical Research Center, the National Health Service or the UK Department of Health and Social Care. M. Yates reports advisory board fees for BioGen. S.E. Sattui is by the Bristol Myers Squibb Foundation Robert A. Winn Diversity in Clinical Trials Career Development Award. S.E. Sattui has received research funding from AstraZeneca and GlaxoSmithKline (clinical trials) and participated in consulting and advisory boards for Sanofi and Amgen (funds toward research support). S.E. Sattui has received speaker fees from Fresenius Kabi (funds toward research support). D.F.L. Liew conceptualized the article, and wrote the original draft. All authors were responsible for drafting, reviewing, and editing the final article.

References

MeSH terms

Substances

LinkOut - more resources